Literature DB >> 22468051

Role of cytokines in the pathogenesis of non-alcoholic Fatty liver disease.

Subir Kumar Das, V Balakrishnan.   

Abstract

UNLABELLED: A number of factors are linked with non-alcoholic fatty liver diseases (NAFLD), a condition that ranges from clinically benign fatty liver to its more severe form, non alcoholic steatohepatitis (NASH). In this study, we evaluated the role of cytokines secreted from adipose tissue in the pathogenesis and progression of NAFLD. We also compared anthropometric profile, lipid profile and insulin resistance data in 105 NAFLD patients with 77 normal subjects. These subjects showed a normal serum albumin level, prothrombin time and renal function but elevated aminotransferases. Predisposing factors were diabetes mellitus (35%), overweight (56%) and hyperlipidemia (44%). Insulin resistance (IR), determined by homeostasis model assessment (HOMA) was confirmed in 70% patients with NAFLD and 42% patients fulfilled the minimum criteria for insulin resistance syndrome (IRS). NAFLD patients showed elevated levels of pro-inflammatory cytokines tumor necrosis factor (TNF)-α, and interleukin (IL)-6, while anti-inflammatory cytokines IL-4 level decreased and IL-10 level remain unchanged; however, TGF-β1 level elevated significantly compared to normal subjects. While insulin level and HOMA-IR both were significantly positively correlated with BMI, waist-to-hip ratio, total cholesterol, VLDL-cholesterol, triglyceride and TGF-β1; glucose, IL-6 and TNF-α levels were significantly positively correlated with HOMA-IR only. In conclusion, pro-inflammatory cytokines play an important link between metabolic and liver disorders in the fat accumulation, and thereby cause IR, inflammation and liver fibrosis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s12291-011-0121-7) contains supplementary material, which is available to authorized users.

Entities:  

Keywords:  Insulin resistance; Interleukin-6; Non-alcoholic fatty liver disease; Transforming growth factor beta; Tumor necrosis factor-alpha

Year:  2011        PMID: 22468051      PMCID: PMC3107419          DOI: 10.1007/s12291-011-0121-7

Source DB:  PubMed          Journal:  Indian J Clin Biochem        ISSN: 0970-1915


  53 in total

1.  Liver fibrosis in overweight patients.

Authors:  V Ratziu; P Giral; F Charlotte; E Bruckert; V Thibault; I Theodorou; L Khalil; G Turpin; P Opolon; T Poynard
Journal:  Gastroenterology       Date:  2000-06       Impact factor: 22.682

2.  Regulation of the acute phase and immune responses: interleukin-6.

Authors: 
Journal:  Ann N Y Acad Sci       Date:  1989       Impact factor: 5.691

3.  Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice.

Authors:  K Tomita; G Tamiya; S Ando; K Ohsumi; T Chiyo; A Mizutani; N Kitamura; K Toda; T Kaneko; Y Horie; J-Y Han; S Kato; M Shimoda; Y Oike; M Tomizawa; S Makino; T Ohkura; H Saito; N Kumagai; H Nagata; H Ishii; T Hibi
Journal:  Gut       Date:  2005-09-20       Impact factor: 23.059

4.  Non-alcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathophysiological aspects.

Authors:  C Loguercio; V De Girolamo; I de Sio; C Tuccillo; A Ascione; F Baldi; G Budillon; L Cimino; A Di Carlo; M P Di Marino; F Morisco; F Picciotto; L Terracciano; R Vecchione; V Verde; C Del Vecchio Blanco
Journal:  J Hepatol       Date:  2001-11       Impact factor: 25.083

Review 5.  [Insulin sensitiviy and lipids].

Authors:  B Vergès
Journal:  Diabetes Metab       Date:  2001-04       Impact factor: 6.041

6.  Body mass index profile in Hong Kong Chinese adults.

Authors:  G T Ko; M M Wu; J Tang; H P Wai; C H Chan; R Chen
Journal:  Ann Acad Med Singapore       Date:  2001-07       Impact factor: 2.473

7.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.

Authors:  Giulio Marchesini; Elisabetta Bugianesi; Gabriele Forlani; Fernanda Cerrelli; Marco Lenzi; Rita Manini; Stefania Natale; Ester Vanni; Nicola Villanova; Nazario Melchionda; Mario Rizzetto
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

Review 8.  Genetics of alcoholic liver disease and nonalcoholic fatty liver disease.

Authors:  Nimantha Mark Wilfred de Alwis; Christopher Paul Day
Journal:  Semin Liver Dis       Date:  2007-02       Impact factor: 6.115

9.  Clinicopathological spectrum of non-alcoholic fatty liver disease among patients in Kerala.

Authors:  Subir Kumar Das; Sukhes Mukherjee; Gaurav Pandey; V Balakrishnan; D M Vasudevan
Journal:  Indian J Clin Biochem       Date:  2009-07-09

Review 10.  Inflammatory pathways and insulin action.

Authors:  G S Hotamisligil
Journal:  Int J Obes Relat Metab Disord       Date:  2003-12
View more
  26 in total

1.  Methods to improve the noninvasive diagnosis and assessment of disease severity in children with suspected nonalcoholic fatty liver disease (NAFLD): Study design.

Authors:  Bryan Rudolph; Nicole Bjorklund; Nadia Ovchinsky; Debora Kogan-Liberman; Adriana Perez; Mark Liszewski; Terry L Levin; Michelle Ewart; Qiang Liu; Xiaonan Xue; Shankar Viswanathan; Howard D Strickler
Journal:  Contemp Clin Trials       Date:  2018-10-27       Impact factor: 2.226

2.  Clinical, anthropometric, biochemical, and histological characteristics of nonobese nonalcoholic fatty liver disease patients of Bangladesh.

Authors:  Shahinul Alam; Utpal Das Gupta; Mahbubul Alam; Jahangir Kabir; Ziaur Rahman Chowdhury; A K M Khorshed Alam
Journal:  Indian J Gastroenterol       Date:  2014-07-15

Review 3.  Have guidelines addressing physical activity been established in nonalcoholic fatty liver disease?

Authors:  Carmine Finelli; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2012-12-14       Impact factor: 5.742

4.  Precision-cut liver slices from diet-induced obese rats exposed to ethanol are susceptible to oxidative stress and increased fatty acid synthesis.

Authors:  Michael J Duryee; Monte S Willis; Courtney S Schaffert; Roger D Reidelberger; Anand Dusad; Daniel R Anderson; Lynell W Klassen; Geoffrey M Thiele
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-11-27       Impact factor: 4.052

5.  Efficacy of Tumor Necrosis Factor and Interleukin-10 Analysis in the Follow-up of Nonalcoholic Fatty Liver Disease Progression.

Authors:  Walid E Zahran; Kholoud A Salah El-Dien; Philip G Kamel; Ahmed Shawky El-Sawaby
Journal:  Indian J Clin Biochem       Date:  2012-07-14

6.  Misoprostol modulates cytokine expression through a cAMP pathway: Potential therapeutic implication for liver disease.

Authors:  Leila Gobejishvili; Smita Ghare; Rehan Khan; Alexander Cambon; David F Barker; Shirish Barve; Craig McClain; Daniell Hill
Journal:  Clin Immunol       Date:  2015-09-25       Impact factor: 3.969

Review 7.  Liver transplantation for nonalcoholic fatty liver disease: new challenges and new opportunities.

Authors:  Mina Shaker; Adam Tabbaa; Mazen Albeldawi; Naim Alkhouri
Journal:  World J Gastroenterol       Date:  2014-05-14       Impact factor: 5.742

8.  Comparative clinical study between the effect of fenofibrate alone and its combination with pentoxifylline on biochemical parameters and liver stiffness in patients with non-alcoholic fatty liver disease.

Authors:  Sahar Mohamed El-Haggar; Tarek Mohamed Mostafa
Journal:  Hepatol Int       Date:  2015-05-09       Impact factor: 6.047

9.  Clinicopathological characteristics and metabolic profiles of non-alcoholic fatty liver disease in Indian patients with normal body mass index: Do they differ from obese or overweight non-alcoholic fatty liver disease?

Authors:  Ramesh Kumar; Archana Rastogi; Manoj Kumar Sharma; Vikram Bhatia; Hitendra Garg; Chhagan Bihari; Shiv Kumar Sarin
Journal:  Indian J Endocrinol Metab       Date:  2013-07

10.  Is melatonin associated with pro-inflammatory cytokine activity and liver fibrosis in non-alcoholic fatty liver disease (NAFLD) patients?

Authors:  Masoudreza Sohrabi; Ali Gholami; Bahareh Amirkalali; Mahsa Taherizadeh; Mahsa Kolahdoz; Fahimeh SafarnezhadTameshkel; Sheida Aghili; Marzieh Hajibaba; Farhad Zamani; Mohsen Nasiri Toosi; Hossein Keyvani
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2021
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.